The US Patent and Trademark Office (USPTO) has issued two additional patents to AcelRx Pharmaceuticals’ sufentanil NanoTab pain products.
The patent entitled Small Volume Oral Transmucosal Dosage Forms Containing Sufentanil for Treatment of Pain claims a dosage form for oral transmucosal administration of sufentanil.
The patent entitled Small-Volume Oral Transmucosal Dosage Forms claims a small-volume solid tablet containing a single dose of sufentanil for oral mucosal administration to a subject.
AcelRx president and CEO Richard King said the addition of these two new patents further strengthens the company’s ability to protect its proprietary technology across the portfolio of sufentanil NanoTab products, including ARX-01, the Sufentanil NanoTab PCA System.
“We will continue to pursue expansion of our patent portfolio worldwide while also focusing on the execution of the ARX-01 Phase 3 clinical program, with data from two Phase 3 studies expected later this year,” King added.
The 8,226,978 patent covers NanoTab technology for delivering sufentanil with claims to a bioadhesive dosage form for oral transmucosal administration to a subject, comprising from about 5 to about 100 micrograms of sufentanil and a volume of less than 30 microliters.
The 8,231,900 patent also covers the composition of sufentanil NanoTabs with claims to a single dose of sufentanil provided as a substantially homogeneous, bioadhesive solid tablet for oral transmucosal administration to a subject, comprising from about 0.25 micrograms to 200 micrograms of sufentanil.
